CSIMarket
 


Bristol myers Squibb Company  (BMY)
Other Ticker:  
 
 

BMY's Revenue Growth by Quarter and Year

Bristol Myers Squibb's Revenue results by quarter and year




BMY Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 11,406.00 11,985.00 11,068.00
III Quarter September - 11,218.00 11,624.00 10,540.00
II Quarter June 11,226.00 11,887.00 11,703.00 10,129.00
I Quarter March 11,337.00 11,648.00 11,073.00 10,781.00
FY   22,563.00 46,159.00 46,385.00 42,518.00



BMY Revenue second quarter 2023 Y/Y Growth Comment
Bristol Myers Squibb Company reported decrease in Revenue in the second quarter 2023 by -5.56% to $ 11,226.00 millions, from the same quarter in 2022.
The decrease in the second quarter 2023 Bristol Myers Squibb Company's Revenue compares unfavorably to the Company's average Revenue growth of 5.89%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Revenue growth. While Bristol Myers Squibb Company' s Revenue decline of -5.56% ranks overall at the positon no. 373 in the second quarter 2023.




BMY Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -4.83 % 8.29 % 39.31 %
III Quarter September - -3.49 % 10.28 % 75.46 %
II Quarter June -5.56 % 1.57 % 15.54 % 61.47 %
I Quarter March -2.67 % 5.19 % 2.71 % 82.11 %
FY   - -0.49 % 9.09 % 62.62 %

Financial Statements
Bristol Myers Squibb's second quarter 2023 Revenue $ 11,226.00 millions BMY's Income Statement
Bristol Myers Squibb's second quarter 2022 Revenue $ 11,887.00 millions Quarterly BMY's Income Statement
New: More BMY's historic Revenue Growth >>


BMY Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 1.68 % 3.11 % 5.01 %
III Quarter September - -5.63 % -0.68 % 4.06 %
II Quarter June -0.98 % 2.05 % 5.69 % -6.05 %
I Quarter March -0.6 % -2.81 % 0.05 % 35.7 %
FY (Year on Year)   - -0.49 % 9.09 % 62.62 %




Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #24
Overall #373

Revenue Y/Y Growth Statistics
High Average Low
62.97 % 5.89 % -24.59 %
(Sep 30 2020)   (March 31, 2013)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #24
Overall #373
Revenue Y/Y Growth Statistics
High Average Low
62.97 % 5.89 % -24.59 %
(Sep 30 2020)   (March 31, 2013)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Bristol Myers Squibb's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
35.7 % 1.35 % -15.91 %
(Mar 31 2020)  


BMY's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Bristol Myers Squibb Company realized decrease in Revenue from the first quarter by -0.98% to $ 11,226.00 millions, from $ 11,337.00 millions achived in the previous quarter.

Albeit seasonal influence normally elevate II. Quarter 2023 results, it simply was not substantial to salvage BMY's II. Quarter 2023 outcome, Lucas L. Anderson, market expert situated in Toronto said and continued that average quarter on quarter Revenue growth is at 1.35% for Bristol Myers Squibb.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 353.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #35
Overall #353
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #35
Overall #353
Revenue Q/Q Growth Statistics
High Average Low
35.7 % 1.35 % -15.91 %
(Mar 31 2020)  


BMY's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Bristol Myers Squibb Company realized decrease in Revenue from the first quarter by -0.98% to $ 11,226.00 millions, from $ 11,337.00 millions achived in the previous quarter.

Albeit cyclical influence commonly elevate II. Quarter 2023 performance, that plainly could not be sufficient to salvage BMY's performance, Lucas L. Anderson, market expert situated in Toronto wrote and continued that average sequential Revenue growth is at 1.35% for Bristol Myers Squibb.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 353.


Bristol Myers Squibb's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 45,187.00 $ 45,848.00 $ 46,159.00 $ 46,738.00 $ 47,144.00
Y / Y Revenue Growth (TTM) -4.15 % -2.37 % -0.49 % 2.79 % 6.22 %
Year on Year Revenue Growth Overall Ranking # 288 # 216 # 1343 # 2328 # 330
Seqeuential Revenue Change (TTM) -1.44 % -0.67 % -1.24 % -0.86 % 0.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 2214 # 326 # 1788 # 225 # 365




Cumulative Revenue growth Comment
Bristol Myers Squibb's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.15% year on year, at Jun 30 2023 compare to the -2.37% decrease at Mar 31 2023. If the Bristol Myers Squibb's fiscal year would end at Jun 30 2023, annual Revenue would be $45,187 millions.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 216 to 288.

Revenue TTM Q/Q Growth Statistics
High Average Low
62.97 %
5.89 %
-24.59 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 127
Healthcare Sector # 17
Overall # 288

Revenue TTM Y/Y Growth Statistics
High Average Low
62.97 %
5.89 %
-24.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 127
Sector # 349
S&P 500 # 2214
Cumulative Revenue growth Comment
Bristol Myers Squibb's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.15% year on year, at Jun 30 2023 compare to the -2.37% decrease at Mar 31 2023. If the Bristol Myers Squibb's fiscal year would end at Jun 30 2023, annual Revenue would be $45,187 millions.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 216 to 288.

Revenue TTM Q/Q Growth Statistics
High Average Low
62.97 %
5.89 %
-24.59 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 127
Healthcare Sector # 17
Overall # 288

Revenue TTM Y/Y Growth Statistics
High Average Low
62.97 %
5.89 %
-24.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 127
Sector # 349
S&P 500 # 2214




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BMY's Competitors
Revenue Growth for Bristol Myers Squibb's Suppliers
Revenue Growth for BMY's Customers

You may also want to know
BMY's Annual Growth Rates BMY's Profitability Ratios BMY's Asset Turnover Ratio BMY's Dividend Growth
BMY's Roe BMY's Valuation Ratios BMY's Financial Strength Ratios BMY's Dividend Payout Ratio
BMY's Roa BMY's Inventory Turnover Ratio BMY's Growth Rates BMY's Dividend Comparisons



Companies with similar Revenue decrease for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Aquestive Therapeutics Inc -0.18%$ -0.181 millions
Phibro Animal Health Corporation-0.34%$ -0.340 millions
Amedisys Inc-0.88%$ -0.882 millions
Baxter International Inc -1.04%$ -1.041 millions
Healthcare Services Group Inc -1.39%$ -1.395 millions
Bio rad Laboratories Inc -1.54%$ -1.536 millions
Harvard Bioscience Inc-1.83%$ -1.832 millions
Embecta Corp -1.92%$ -1.924 millions
Enhabit Inc -2.13%$ -2.127 millions
Icu Medical Inc-2.26%$ -2.260 millions
Tandem Diabetes Care Inc -2.26%$ -2.261 millions
West Pharmaceutical Services Inc -2.27%$ -2.269 millions
Coherus Biosciences inc -2.39%$ -2.386 millions
Hookipa Pharma inc -2.44%$ -2.440 millions
Biolife Solutions Inc -2.53%$ -2.529 millions
Inspiremd Inc -2.61%$ -2.613 millions
Enanta Pharmaceuticals Inc-3.01%$ -3.014 millions
National Research Corporation-3.03%$ -3.033 millions
Intellia Therapeutics Inc -3.11%$ -3.108 millions
Orgenesis Inc -3.14%$ -3.138 millions
Organogenesis Holdings Inc -3.36%$ -3.365 millions
Marker Therapeutics inc -3.52%$ -3.523 millions
Akumin Inc -3.79%$ -3.793 millions
Endo International Plc-3.91%$ -3.912 millions
Zimvie Inc -4.12%$ -4.122 millions
Integra Lifesciences Holdings Corp-4.16%$ -4.160 millions
Universal Biosensors Inc -4.18%$ -4.177 millions
Sonendo Inc -4.26%$ -4.257 millions
Avinger Inc -4.27%$ -4.268 millions
Fuse Medical Inc -4.27%$ -4.271 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com